These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22106827)

  • 1. Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.
    Kober C; Johnson M; Fisher M; Hill T; Anderson J; Bansi L; Gompels M; Palfreeman A; Dunn D; Gazzard B; Gilson R; Post F; Phillips AN; Walsh J; Orkin C; Delpech V; Ainsworth J; Leen C; Sabin CA;
    HIV Med; 2012 Jan; 13(1):73-8. PubMed ID: 22106827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.
    Lourenço L; Samji H; Nohpal A; Chau W; Colley G; Lepik K; Barrios R; Lima V; Hogg RS; Montaner J; Kesselring S; Moore DM
    HIV Med; 2015 Jul; 16(6):337-45. PubMed ID: 25721157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV DNA and immune alteration during successful HAART.
    Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
    Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
    Minidis NM; Mesner O; Agan BK; Okulicz JF
    J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali.
    Merci NM; Emerence U; Augustin N; Habtu M; Julie I; Angelique T; Jessica B; Cynthia A; Penda AT
    Pan Afr Med J; 2017; 26():14. PubMed ID: 28450993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive role of CD4
    Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
    BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
    Porter K; Walker S; Hill T; Anderson J; Leen C; Johnson M; Gazzard B; Walsh J; Fisher M; Orkin C; Schwenk A; Gilson R; Easterbrook P; Delpech V; Sabin CA;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):202-5. PubMed ID: 17971709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
    Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.